molecules

MDPI

Article

Involvement of the Hydroperoxy Group in the Irreversible Inhibition of Leukocyte-Type 12-Lipoxygenase by Monoterpene Glycosides Contained in the Qing Shan Lu Shui Tea

Yuki Kawakami [1], Akemi Otsuki [1], Yoshiko Mori [1,2], Keita Kanzaki [1,3], Toshiko Suzuki-Yamamoto [1] , Ding Zhi Fang [4], Hideyuki Ito [1] and Yoshitaka Takahashi [1,*]

1   Department of Nutritional Science, Faculty of Health and Welfare Science, Okayama Prefectural University, 111 Kuboki, Soja, Okayama 719-1197, Japan; kawaka@fhw.oka-pu.ac.jp (Y.K.); okapu.1222041akemi@gmail.com (A.O.); tyche55cbm@gmail.com (Y.M.); keita.kanzaki@mw.kawasaki-m.ac.jp (K.K.); toshiko@fhw.oka-pu.ac.jp (T.S.-Y.); hito@fhw.oka-pu.ac.jp (H.I.)
2   Department of Human Nutrition, Faculty of Contemporary Human Life Science, Chugoku Gakuen University, 83 Niwase, Kita-ku, Okayama 701-0197, Japan
3   Department of Clinical Nutrition, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare, 288 Matsushima, Kurashiki, Okayama 701-0193, Japan
4   Department of Biochemistry and Molecular Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, 17 Section 3, South Renmin Road, Chengdu 610041, China; dzfang@scu.edu.cn
*   Correspondence: ytaka@fhw.oka-pu.ac.jp; Tel.: +81-866-94-2155

check for updates

Abstract: We have previously found two novel monoterpene glycosides, liguroside A and liguroside B, with an inhibitory effect on the catalytic activity of the enzyme leukocyte-type 12-lipoxygenase in the Qing Shan Lu Shui tea. Here, two new monoterpene glycosides, liguroside C and liguroside D which inhibit this enzyme, were isolated from the same tea. The spectral and chemical evidence characterized the structures of these compounds as (5*E*)-7-hydroperoxy-3,7-dimethyl-1,5 -octadienyl-3-*O*-(α-L-rhamnopyranosyl)-(1''→3')-(4'''-*O-trans-p*-coumaroyl)-β-D-glucopyranoside and (2*E*)-6-hydroxy-3,7-dimethyl-2,7-octadienyl-3-*O*-(α-L-rhamnopyranosyl)-(1''→3')-(4'''-*O-trans-p*-coumaroyl)-β-D-glucopyranoside, respectively. These ligurosides, which irreversibly inhibited leukocyte-type 12-lipoxygenase, have a hydroperoxy group in the monoterpene moiety. Additionally, monoterpene glycosides had the same backbone structure but did not have a hydroperoxy group, such as kudingoside A and lipedoside B-III, contained in the tea did not inhibit the enzyme. When a hydroperoxy group in liguroside A was reduced by using triphenylphosphine, the resultant compound, kudingoside B, showed a lower inhibitory effect on the enzyme. These results strongly suggest the involvement of the hydroperoxy group in the irreversible inhibition of the catalytic activity of leukocyte-type 12-lipoxygenase by the monoterpene glycosides contained in the Qing Shan Lu Shui tea.

1. Introduction

Qing Shan Lu Shui which is a kind of Kuding tea, is made by processing the leaves of *Ligustrum robustum* (Roxb.) Blume. The genus *Ligustrum* in the family Oleaceae contains phenolic constituents such as quinic acid derivatives, flavonoids, and monoterpene glycosides, and shows in vitro antioxidative activity [1]. Qing Shan Lu Shui tea is consumed in some parts of China, for

health-benefits; it shows various pharmacological effects, such as anti-inflammatory, antioxidative, and antiproliferative activities [2–6]. A previous report has demonstrated that aqueous extracts of the processed leaves of *Ligustrum robustum*, dose-dependently scavenged superoxide radicals, inhibited lipid peroxidation, and prevented hemolysis of the red blood cells [2]. We have previously reported that two novel monoterpene glycosides, liguroside A and liguroside B, inhibited the catalytic activity of leukocyte-type 12-lipoxygenase (Figure 1) [7]. Leukocyte-type 12-lipoxygenase not only oxygenates the free fatty acids (such as arachidonic acid) to produce 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid (12-HPETE), but also fatty acids that have esterified to cholesterol in the low-density lipoprotein (LDL) particle, which contributes to the formation of oxidized LDL and the development of atherosclerosis [8,9]. Our previous report demonstrated that guava leaf extracts inhibited the leukocyte-type 12-lipoxygenase activity, as well as cell-mediated LDL oxidation, and attenuated the development of atherosclerosis in apoE-knockout mice [10]. To further elucidate the beneficial components contained in the Qing Shan Lu Shui, we isolated novel monoterpene glycosides showing inhibitory effects on the leukocyte-type 12-lipoxygenase activity from the Qing Shan Lu Shui. We have also reported that the inhibitors from the Qing Shan Lu Shui irreversibly inhibit the catalytic activity of leukocyte-type 12-lipoxygenase.

Figure 1. Structures of the known monoterpene glycosides; (**1**) liguroside A, (**2**) liguroside B, (**5**) lipedoside B-III, (**6**) kudingoside B, and (**7**) kudingoside A.

2. Results and Discussion

In the present study, we isolated two new monoterpene glycosides, liguroside C and liguroside D, which inhibited the leukocyte-type 12-lipoxygenase from the Qing Shan Lu Shui tea.

Liguroside C, an off-white amorphous powder, exhibited an HRESIMS peak at *m/z* 639.2650 $[M - H]^-$ (calcd. for $C_{31}H_{43}O_{14}$, 639.2658). The ^{1}H-NMR spectrum of liguroside A displayed signals due to a *trans p*-coumaroyl group [δ 7.51 (2H, d, *J* = 8.4 Hz), δ 6.85 (2H, d, *J* = 8.4 Hz), δ 7.64 (1H, d, *J* = 15.6 Hz), and 6.33 (1H, d, *J* = 15.6 Hz)], in the aromatic proton region. The existence of β-glucosyl and α-rhamnosyl moieties was deduced by two anomeric proton signals at δ 4.78 (d, *J* = 7.8 Hz) and δ 5.17 (brs), respectively. Proton signals due to an exomethylene (δ 5.19 and 5.18), three vinyls (δ 5.92,

5.63 and 5.59), a methylene (δ 2.32), and three tertiary methyl (δ 1.31, 1.22, 1.22) groups were observed in the aliphatic proton region (Table 1 and Figure S1). The ^{13}C-NMR resonances of liguroside C were similar to those of liguroside A [7], except for 10 signals of a monoterpene moiety (Table 1 and Figures S2–S5). The monoterpene moiety was assigned as a (5*E*)-3,7-dimethyl-1,5-octadiene-3,7-diol analogue, based on the correlations from the HMBC experiment of liguroside C, as shown in Figure 2. Among the signals of monoterpene unit, the signals of the two methyls (δ 24.8, C-8, 9) and those attached to the oxygenated tertiary carbon (δ 81.6, C-7) were close to those due to the methyls (δ 24.1) and the methine (δ 80.6) carbons of liguroside A [7], suggesting that a hydroperoxy group was allocated to the C-7 position of liguroside C; this suggestion was supported by its high-resolution electrospray ionization mass spectroscopy (HRESIMS) analysis. On the basis of these data, the structure of liguroside C was concluded to be (5*E*)-7-hydroperoxy-3,7-dimethyl-1,5-octadienyl-3-*O*-(α-L-rhamnopyranosyl)-(1″→3′)-(4‴-*O*-*trans*-*p*-coumaroyl)-β-D-glucopyranoside (Figure 2).

Table 1. ^{1}H- and ^{13}C-NMR data of ligurosides C and D in acetone-d_6-D$_2$O (9:1, *v/v*) (δ$_H$: 600 MHz; δ$_C$: 151 MHz).

| Position	Liguroside C		Liguroside D	
	δ$_H$ (*J* in Hz)	δ$_C$	δ$_H$ (*J* in Hz)	δ$_C$
Monoterpene				
1	5.19 brd (18)	115.9	4.22 m	65.8
	5.18 brd (10.8)		4.32 dd (6, 12)	
2	5.92 dd (10.8, 18)	143.3	5.35 brt (6.6)	121.4
3		80.7		140.8
4	2.32 d (6)	44.7	2.03 m	36.0
5	5.63 dd (6, 15.6)	125.8	1.54 m, 1.64 m	29.5
6	5.59 d (15.6)	138.5	4.21 m	88.8
7		81.6		145.4
8	1.22 s	24.8	4.89 brs, 4.90 brs	113.7
9	1.22 s	24.8	1.67 s	17.0
10	1.31 s	23.1	1.65 s	16.3
Glucosyl				
1′	4.78 d (7.8)	98.6	4.41 d (7.8)	101.9
2′	3.38 brt (9)	75.5	3.40 brt (9)	75.5
3′	3.78 t (9)	80.8	3.81 t (9)	80.8
4′	4.85 t (9)	70.2	4.86 t (9)	70.2
5′	3.52 m	75.2	3.52 m	75.5
6′	3.54 m, 3.46 m	61.8	3.56 m, 3.49 m	61.9
Rhamnosyl				
1″	5.17 brs	102.1	5.17 brs	102.2
2″	3.90 m	71.5	3.90 m	71.5
3″	3.54 m	71.6	3.54 m	71.6
4″	3.29 t (9.6)	72.9	3.29 t (9.6)	73.0
5″	3.51 m	69.6	3.51 m	69.6
6″	1.02 d (6.6)	18.3	1.02 d (6.6)	18.3
Coumaroyl				
1‴		126.3		126.4
2‴	7.51 d (8.4)	131.0	7.51 d (8.4)	131.0
3‴	6.85 d (8.4)	116.6	6.86 d (8.4)	116.6
4‴		160.8		160.8
5‴	6.85 d (8.4)	116.6	6.86 d (8.4)	116.6
6‴	7.51 d (8.4)	131.0	7.51 d (8.4)	131.0
7‴	7.64 d (15.6)	146.7	7.63 d (15.6)	146.7
8‴	6.33 d (15.6)	114.5	6.33 d (15.6)	114.5
9‴		167.5		167.5

**Figure 2.** Structures of the new monoterpene glycosides, ligurosides C (**3**) and D (**4**).

Liguroside D was obtained as an off-white amorphous powder, which has the molecular formula $C_{31}H_{44}O_{14}$, based on a pseudomolecular ion peak at *m/z* 639.2644 [M − H]⁻ (calcd. for $C_{31}H_{43}O_{14}$, 639.2658) in the HRESIMS. The ¹H- and ¹³C-NMR data corresponding to the acyl and glycosyl moieties of liguroside D were close to those of liguroside C, suggesting that an α-L-rhamnopyranosyl)-(1″→3′)-(4‴-*O-trans-p*-coumaroyl)-β-D-glucopyranosyl unit is present in liguroside D. The ¹H- and ¹³C-NMR data of liguroside D, except for the signals due to the acyl and glycosyl units, showed the signals of an exomethylene (δ_H 4.89, 4.90; δ_C 113.7), a vinyl (δ_H 5.35; δ_C 121.4), oxygenated methine (δ_H 4.21; δ_C 88.8) and methylene (δ_H 4.32, 4.22; δ_C 65.8), mutually coupled methylenes (δ_H 2.03, 1.64, 1.56; δ_C 36.0, 29.5), two vinyl methyls (δ_H 1.67, 1.65; δ_C 17.0, 16.3), and two sp^2 carbons (δ_C 145.4, 140.8) (Table 1 and Figures S6–S9). The NMR data of the monoterpene unit (Table 1) and the HMBC experiment of liguroside D (Figure 2 and Figure S10) suggested that the (2*E*)-6-hydroxy-3,7-dimethyl-2,7-octadien-1-ol analogue was involved in liguroside D, as a monoterpene unit. The significant downfield shift of the oxygenated methine resonance (δ_C 88.8) and HRESIMS data of liguroside D showed that the hydroxy group of C-6 position in liguroside D is replaced by the hydroperoxy group [11]. The NMR feature including the HMBC correlations of liguroside D confirmed that the structure of liguroside D was assigned to (2*E*)-6-hydroxy-3,7-dimethyl-2,7-octadienyl-3-*O*-(α-L-rhamnopyranosyl)-(1″→3′)-(4‴-*O-trans-p*-coumaroyl)-β-D-glucopyranoside (Figure 2).

As shown in Figure 3, liguroside C and liguroside D, dose-dependently inhibited the leukocyte-type 12-lipoxygenase activity with IC₅₀ values of 2.9 µM and 4.2 µM, respectively. The inhibitory potencies of liguroside C and liguroside D were comparable to those of liguroside A and liguroside B (IC₅₀ values of 1.7 µM and 0.7 µM) [7]. In our previous study, the leukocyte-type 12-lipoxygenase inhibitory assay-guided fractionation of the 30% aqueous ethanol soluble portion of the ethyl acetate extract was carried out using a reversed-phase HPLC [7]. We analyzed the obtained active fraction containing ligurosides A, B, C, and D using a reversed-phase HPLC (Figure S11A). Ligurosides C and D were separated by another HPLC condition (Figure S11B). Our previous report indicated that the contents of ligurosides A and B in the Qing Shan Lu Shui leaves were 0.85% and 0.31% (*w/w*), respectively [7]. The contents of ligurosides C and D were 0.23% and 0.50% (*w/w*), respectively.

Leukocyte-type 12-lipoxygenase shows an irreversible suicidal inactivation in which the reaction ceases within a few minutes resulting in a by-product of 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid [12,13]. As all four compounds which inhibited leukocyte-type 12-lipoxygenase had a hydroperoxy group in the monoterpene moiety, we tested the reversibility of the leukocyte-type 12-lipoxygenase inhibition by ligurosides. The leukocyte-type 12-lipoxygenase was preincubated for 5 min with 6 µM of each liguroside or quercetin (used as a control of reversible inhibition of the enzyme), either of which almost completely inhibited the enzyme activity. The preincubation mixture was 200-fold diluted 0, 5, 15, and 30 min, before starting the enzyme reaction under the standard condition for the lipoxygenase assay. As shown in Figure 4, the leukocyte-type 12-lipoxygenase activity was quickly recovered after dilution of quercetin and the inhibition was hardly observed after 15 min. On the other hands, tested ligurosides inhibited the leukocyte-type 12-lipoxygenase activity, even after 30 min, indicating an irreversible inhibition of the enzyme activity (Figure 4).

Figure 3. Inhibition of the leukocyte-type 12-lipoxygenase activity by liguroside C (closed circles) and liguroside D (open circles). Leukocyte-type 12-lipoxygenase was incubated with 25 μM arachidonic acid at 30 °C for 5 min in the standard reaction mixture, in the presence of inhibitors at various concentrations and the products were quantified using a reverse-phase HPLC. Relative enzyme activities, as compared with the activity without inhibitors, are shown.

Figure 4. Reversibility analysis of the leukocyte-type 12-lipoxygenase inhibition. The leukocyte-type 12-lipoxygenase was preincubated with 6 μM quercetin, liguroside A, liguroside C, and liguroside D, at 30 °C, for 5 min, and then the mixture was 200-fold diluted in the standard lipoxygenase reaction mixture. After 0, 5, 15, and 30 min, the mixtures were incubated with 25 μM arachidonic acid at 30 °C, for 5 min. The reaction without dilution of inhibitors (no dilution) was also carried out. The relative enzyme activities, as compared with the activity without inhibitors, are shown.

p-Coumaric acid, as a part of the ligurosides, showed no inhibition on the leukocyte-type 12-lipoxygenase activity, suggesting that the inhibitory effects of liguroside A and liguroside B can be attributed to the monoterpene unit with the hydroperoxy group [7]. On the other hand, monoterpene glycosides have the same backbone structure but did not have a hydroperoxy group (such as kudingoside A and lipedoside B-III) contained in the tea (Figure 1), and did not inhibit the enzyme activity (Figure 5). We reduced a hydroperoxy group in liguroside A using triphenylphosphine. The structure of the reduced compound was confirmed by mass spectrometry as kudingoside B, as described previously (Figure 1) [7]. The resultant compound, kudingoside B, showed a lower inhibitory effect on the enzyme (Figure 5), strongly suggesting that the hydroperoxy group of ligurosides played a key role in the irreversible inhibition of the leukocyte-type 12-lipoxygenase by the compounds. The detailed mechanism of the enzyme inhibition by the hydroperoxy group of ligurosides remains to be elucidated. In the suicidal inactivation of the enzyme, 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid was further converted to 14,15-leukotriene A_4, an epoxide product, by the leukocyte-type 12-lipoxygenase, itself, and was incorporated into the enzyme protein, by a covalent binding [12]. In contrast, 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid, a major product of the leukocyte-type 12-lipoxyganase, did not inactivate the enzyme as fast as the 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid, and slowly incorporated into the enzyme that did not bind covalently [12]. It is well-known

that terpenes, such as linalool and geraniol can autoxidize and form oxidation products such as hydroperoxides, when exposed to air [14]. It was also reported that the hydroxy-group-esterified linalyl acetate oxidizes on air-exposure, forming hydroperoxides, which then turns into epoxide [15]. Therefore, the liguroside epoxides derived from the hydroperoxy group of the ligurosides might contribute to the irreversible inhibition of the leukocyte-type 12-lipoxygenase.

Figure 5. Inhibition of the leukocyte-type 12-lipoxygenase activity by liguroside A (closed circles), kudingoside B (grey circles), kudingoside A (open circles), and lipedoside B-III (open lozenges). Leukocyte-type 12-lipoxygenase was incubated with 25 μM arachidonic acid, at 30 °C, for 5 min, in the standard reaction mixture in the presence of inhibitors, at various concentrations, and the products were quantified using a reverse-phase HPLC. Relative enzyme activities, as compared with the activity without inhibitors, are shown.

We investigated whether the ligurosides affect the catalytic activities of the arachidonic acid, metabolizing enzymes other than the leukocyte-type 12-lipoxygenase. As shown in Figure 6, liguroside A also inhibited 15-lipoxygenase, cyclooxygenase-1, and cyclooxygenase-2, with IC_{50} values of 3.2, 21.5, and 16.9 μM, respectively. In contrast, platelet-type 12-lipoxygenase was almost unaffected by liguroside A up to 100 μM. Kishimoto et al. reported that the platelet-type 12-lipoxygenase did not show a rapid inactivation by the 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid, presumably because the enzyme hardly converted the 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid to an epoxide product [12]. It is known that suicidal inactivation is hardly observed in the platelet-type 12-lipoxygenase that did not produce the 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid as a by-product [12]. Further investigation is necessary to elucidate the mechanism of inhibition of the leukocyte-type 12-lipoxygenase by the ligurosides.

Figure 6. Inhibition of various lipoxygenase and cyclooxygenase activities by liguroside A. Reactions were carried out under the standard conditions in the presence of liguroside A at various concentrations and the products were quantified, using a reverse-phase HPLC. Relative enzyme activities of the 15-lipoxygenase-1 (closed circles), platelet-type 12-lipoxygenase (open circles), 5-lipoxygenase (open lozenges), cyclooxygenase-1 (open triangles), and cyclooxygenase-2 (closed triangles), as compared to the activity without inhibitors, are shown.

3. Materials and Methods

3.1. Materials

Arachidonic acid was obtained from the Nu-Chek prep (Elysian, MN, USA). Authentic 15-hydroxy-11,13-eicosadienoic acid (15-HEDE) was prepared by the incubation of soybean lipoxygenase type I (Sigma-Aldrich, St. Louis, MO, USA), with 11,14-eicosadienoic acid (Cayman Chemical, Ann Arbor, MI, USA), followed by purification with HPLC [9]. Kudingoside B was prepared by the incubation of liguroside A, with triphenylphosphine, as previously described [7]. All other reagents and chemicals were commercially available as extra-pure-grade products.

3.2. Isolation of the Monoterpene Glycosides

The aqueous ethanol extract of the Qing Shan Lu Shui was prepared, as described previously [7]. Briefly, the dried leaves of the Qing Shan Lu Shui were extracted with 50% aqueous ethanol. After filtration and evaporation of the extract, the residue was partitioned between water and ethyl acetate. The organic layer was evaporated, and then, the resulting residue was re-dissolved with 45% aqueous methanol or 53% aqueous methanol. The 45% aqueous methanol extract was separated by a preparative HPLC, to afford liguroside C (retention time 31.5 min) and liguroside D (retention time was 37.6 min). HPLC was performed on a Waters Alliance 2695 separations module. Reverse-phase HPLC in an isocratic condition was conducted on a COSMOSIL Cholester column (5-μm particle, 250 $\times$ 4.6 mm i.d., Nacalai, Kyoto, Japan), developed with methanol–water–acetic acid (45:55:0.01, v/v), at 40 °C and a flow rate of 1.0 mL/min. Detection was affected at 200–700 nm. The 53% aqueous methanol extract was separated by a preparative HPLC to afford the kudingoside A (retention time 31.5 min) and lipedoside B-III (retention time 37.6 min). HPLC was performed under the same conditions as those described above, but was not developed with methanol-ater-acetic acid (53:47:0.01, v/v).

3.3. Structural Analysis

^{1}H- and ^{13}C-NMR spectra were measured in acetone-d_6 on a Varian NMR System 600 MHz (600 MHz for ^{1}H-NMR and 151 MHz for ^{13}C-NMR) instrument; chemical shifts were given in δ (ppm) values, relative to that of the solvent (δ_H: 2.04; δ_C: 29.8), on a tetramethylsilane scale. The standard pulse sequences programmed for the instrument were used for each 2D-NMR experiment (^{1}H-^{1}H COSY, HSQC, and HMBC). The J_{CH} value was set at 8 Hz in the HMBC experiment. Mass spectra were obtained on a Bruker MicrOTOF II spectrometer (Bruker, Billerica, MA, USA), using ESI source in a negative-ion mode.

3.4. Enzyme Assay

The lipoxygenase and cyclooxygenase reactions were carried out, as described previously [9,10,16]. Briefly, leukocyte-type 12-lipoxygenase or 15-lipoxygenase-1 was preincubated with inhibitors, in a volume of 0.2 mL in 100 mM Tris-HCl buffer, at pH 7.4, for 5 min at 30 °C, and was then incubated with 25 μM arachidonic acid for 5 min at 30 °C. Platelet-type 12-lipoxygenase reaction was carried out the as same as leukocyte-type 12-lipoxygenase reaction, except for incubation condition of 30 min at 37 °C. 5-Lipoxygenase was preincubated in 100 mM Tris-HCl buffer at pH 7.4, 2 mM CaCl$_2$, and 2 mM ATP, with inhibitors, for 5 min on ice and then incubated with 25 μM arachidonic acid, for 5 min at 30 °C. To reduce the metabolites of each lipoxygenase isozyme, we added glutathione peroxidase (0.1 unit) and 5 mM glutathione to the mixture, followed by incubation for another 20 min. The enzyme reactions of cyclooxygenase-1 and cyclooxygenase-2 were carried out, as described previously [10,17]. Briefly, cyclooxygenase-1 and cyclooxygenase-2 were preincubated with inhibitors in a volume of 0.2 mL in 100 mM Tris-HCl buffer at pH 7.4, 2 μM hematin, and 5 mM tryptophan, for 5 min at 24 °C, and then incubated with 25 μM linoleic acid, for 5 min at 24 °C. After the reaction was quenched by an addition of 50 mM HCl, 0.5 nmol of 15-HEDE were added as an internal standard for enzyme reactions. The products extracted with ice-cold diethyl ether were analyzed by a reverse-phase HPLC, using a

Waters Alliance system equipped with a COSMOSIL 5C18-MS-II column (5-µm particle, 250 × 4.6 mm i.d., Nacalai), with a solvent system of methanol-water-acetic acid (80:20:0.01, *v/v*), at a flow rate of 1 mL/min, as previously described [17]. Absorption at 235 nm was continuously monitored, using a Waters 2489 UV/Visible detector (Waters, Milford, MA, USA). Protein concentration was determined using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA), with bovine serum albumin as a standard.

Supplementary Materials: The following are available online, Figure S1: ^{1}H-NMR spectrum of liguroside C in acetone-d_6-D$_2$O (9:1, *v/v*) (600 MHz); Figure S2: ^{13}C-NMR spectrum of liguroside C in acetone-d_6-D$_2$O (9:1, *v/v*) (151 MHz); Figure S3: ^{1}H-^{1}H COSY NMR spectrum of liguroside C in acetone-d_6-D$_2$O (9:1, *v/v*) (600 MHz); Figure S4: HSQC NMR spectrum of liguroside C in acetone-d_6-D$_2$O (9:1, *v/v*) (600 MHz); Figure S5: HMBC NMR spectrum of liguroside C in acetone-d_6-D$_2$O (9:1, *v/v*) (600 MHz); Figure S6: ^{1}H-NMR spectrum of liguroside D in acetone-d_6-D$_2$O (9:1, *v/v*) (600 MHz); Figure S7: ^{13}C-NMR spectrum of liguroside D in acetone-d_6-D$_2$O (9:1, *v/v*) (151 MHz); Figure S8: ^{1}H-^{1}H COSY NMR spectrum of liguroside D in acetone-d_6-D$_2$O (9:1, *v/v*) (600 MHz); Figure S9: HSQC NMR spectrum of liguroside D in acetone-d_6-D$_2$O (9:1, *v/v*) (600 MHz); Figure S10: HMBC NMR spectrum of liguroside D in acetone-d_6-D$_2$O (9:1, *v/v*) (600 MHz); Figure S11: HPLC profiles of ligurosides A, B, C, and D.

References

1. Zhu, F.; Cai, Y.Z.; Sun, M.; Ke, J.; Lu, D.; Corke, H. Comparison of major phenolic constituents and in vitro antioxidant activity of diverse Kudingcha genotypes from *Ilex kudingcha*, *Ilex cornuta*, and *Ligustrum robustum*. *J. Agric. Food Chem.* **2009**, *57*, 6082–6089. [CrossRef] [PubMed]

2. Lau, K.M.; He, Z.D.; Dong, H.; Fung, K.P.; But, P.P. Anti-oxidative, anti-inflammatory and hepato-protective effects of *Ligustrum robustum*. *J. Ethnopharmacol.* **2002**, *83*, 63–71. [CrossRef]

3. Yu, Z.L.; Zeng, W.C. Antioxidant, antibrowning, and cytoprotective activities of *Ligustrum robustum* (Rxob.) Blume extract. *J. Food Sci.* **2013**, *78*, 1354–1362. [CrossRef] [PubMed]

4. Xie, Z.M.; Zhou, T.; Liao, H.Y.; Ye, Q.; Liu, S.; Qi, L.; Huang, J.; Zuo, H.J.; Pei, X.F. Effects of *Ligustrum robustum* on gut microbes and obesity in rats. *World J. Gastroenterol.* **2015**, *21*, 13042–13054. [CrossRef] [PubMed]

5. Yang, R.M.; Liu, F.; He, Z.D.; Ji, M.; Chu, X.X.; Kang, Z.Y.; Cai, D.Y.; Gao, N.N. Anti-obesity effect of total phenylpropanoid glycosides from *Ligustrum robustum* Blume in fatty diet-fed mice via up-regulating leptin. *J. Ethnopharmacol.* **2015**, *169*, 459–465. [CrossRef] [PubMed]

6. Zuo, H.J.; Liu, S.; Yan, C.; Li, L.M.; Pei, X.F. In vitro and in vivo evaluation of antitumor activity of *Ligustrum robustum*, a Chinese herbal tea. *Chin. J. Integr. Med.* **2018**. [CrossRef] [PubMed]

7. Ito, H.; Otsuki, A.; Mori, H.; Li, P.; Kinoshita, M.; Kawakami, Y.; Tsuji, H.; Fang, D.Z.; Takahashi, Y. Two new monoterpene glycosides from Qing Shan Lu Shui tea with inhibitory effects on leukocyte-type 12-lipoxygenase activity. *Molecules* **2013**, *18*, 4257–4266. [CrossRef] [PubMed]

8. Cyrus, T.; Witztum, J.L.; Rader, D.J.; Tangirala, R.; Fazio, S.; Linton, M.F.; Funk, C.D. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. *J. Clin. Invest.* **1999**, *103*, 1597–1604. [CrossRef]

9. Sakashita, T.; Takahashi, Y.; Kinoshita, T.; Yoshimoto, T. Essential involvement of 12-lipoxygenase in regiospecific and stereospecific oxidation of low density lipoprotein by macrophages. *Eur. J. Biochem.* **1999**, *265*, 825–831. [CrossRef] [PubMed]

10. Kawakami, Y.; Hosokawa, T.; Morinaka, T.; Irino, S.; Hirano, S.; Kobayashi, H.; Yoshioka, A.; Suzuki-Yamamoto, T.; Yokoro, M.; Kimoto, M.; et al. Antiatherogenic effect of guava leaf extracts inhibiting leucocyte-type 12-lipoxygenase activity. *Food Chem.* **2012**, *131*, 1069–1075. [CrossRef]

11. Karikura, M.; Miyase, T.; Tanizawa, H.; Taniyama, T.; Takino, Y. Studies on absorption, distribution, excretion and metabolism of ginseng saponins. VI. The decomposition products of ginsenoside Rb2 in the stomach of rats. *Chem. Pharm. Bull.* **1991**, *39*, 400–404. [CrossRef] [PubMed]

12. Kishimoto, K.; Nakamura, M.; Suzuki, H.; Yoshimoto, T.; Yamamoto, S.; Takao, T.; Shimonishi, Y.; Tanabe, T. Suicide inactivation of porcine leukocyte 12-lipoxygenase associated with its incorporation of 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid derivative. *Biochim. Biophys. Acta* **1996**, *1300*, 56–62. [CrossRef]

13. Wiesner, R.; Suzuki, H.; Walther, M.; Yamamoto, S.; Kuhn, H. Suicidal inactivation of the rabbit 15-lipoxygenase by 15S-HpETE is paralleled by covalent modification of active site peptides. *Free Radic. Biol. Med.* **2003**, *34*, 304–315. [CrossRef]

14. Skold, M.; Borje, A.; Harambasic, E.; Karlberg, A.T. Contact allergens formed on air exposure of linalool. Identification and quantification of primary and secondary oxidation products and the effect on skin sensitization. *Chem. Res. Toxicol.* **2004**, *17*, 1697–1705. [CrossRef] [PubMed]

15. Skold, M.; Hagvall, L.; Karlberg, A.T. Autoxidation of linalyl acetate, the main component of lavender oil, creates potent contact allergens. *Contact Dermatitis* **2008**, *58*, 9–14. [CrossRef] [PubMed]

16. Suzuki, H.; Miyauchi, D.; Yamamoto, S. A selective inhibitor of arachidonate 5-lipoxygenase scavenging peroxide activator. *Biochem. Pharmacol.* **1997**, *54*, 529–532. [CrossRef]

17. Kawakami, Y.; Nakamura, T.; Hosokawa, T.; Suzuki-Yamamoto, T.; Yamashita, H.; Kimoto, M.; Tsuji, H.; Yoshida, H.; Hada, T.; Takahashi, Y. Antiproliferative activity of guava leaf extract via inhibition of prostaglandin endoperoxide H synthase isoforms. *Prostaglandins Leukot. Essent. Fatty Acids* **2009**, *80*, 239–245. [CrossRef] [PubMed]

Sample Availability: Samples of the compounds are not available from the authors.